Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients (FUMANCE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02383030|
Recruitment Status : Unknown
Verified June 2016 by Consorzio Oncotech.
Recruitment status was: Recruiting
First Posted : March 9, 2015
Last Update Posted : June 15, 2016
Clinical Research Technology S.r.l.
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||September 2017|
|Estimated Study Completion Date :||December 2017|